One of the reasons that drug development is so expensive and time consuming is the cost of clinical trial failures. A critical means of accelerating drug development and reducing its cost lies in identifying candidates during preclinical development that have risks that outweigh their benefits and eliminating them from the pipeline before they advance to the clinic. We spoke to Sarah Gould, Director and Senior Principal Scientific Advisor for Charles River Labs, about the types of risks that can be detected through preclinical testing, strategies that can be used to de-risk programs, and why doing so in the current environment can take on growing importance for companies seeking funding or licensing agreements.

Why Failure Can Be a Faster Path to Success

The Big4Bio Podcast shares podcasts that give insight and information about/from biotech and life science leaders and organizations within the Big4Bio regions. Check out our Playlists to hear podcasts by region.